Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1

Conditions

Lymphoma, T-Cell, Cutaneous 5Mycosis Fungoides 3Multiple Myeloma 3Hodgkin Disease 3Lymphoma, T-Cell, Peripheral 2Lymphoma, Non-Hodgkin 2Lymphoma, Mantle-Cell 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, Follicular 2Lymphoma, B-Cell, Marginal Zone 2Leukemia, Lymphocytic, Chronic, B-Cell 2Breast Neoplasms 2Waldenstrom Macroglobulinemia 1Urinary Bladder Neoplasms 1Urethral Neoplasms 1Stomach Neoplasms 1Somatostatinoma 1Sezary Syndrome 1Neoplasms 1Melanoma 1Lymphoma, T-Cell 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma 1Insulinoma 1Inflammatory Breast Neoplasms 1Glucagonoma 1Gastrinoma 1Esophageal Neoplasms 1Carcinoma, Ovarian Epithelial 1Carcinoma, Islet Cell 1

Interventions

Everolimus 2romidepsin 1pentetreotide 1folfirinox 1Sunitinib 1Oxaliplatin 1Octreotide 1Leucovorin 1Granulocyte Colony-Stimulating Factor 1Fluorouracil 1Filgrastim 1Doxorubicin 1Cytokines 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Carcinoma, Islet Cell × romidepsin × Clear all
NCT00084461 2013-06-04

Romidepsin in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors

National Cancer Institute (NCI)

Phase 2 Terminated
25 enrolled
Endocrine

Glucagonoma, Insulinoma, Somatostatinoma, Gastrinoma, Carcinoma, Islet Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡